Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells

被引:30
|
作者
Bashash, Davood [1 ,2 ]
Ghaffari, Seyed H. [2 ]
Mirzaee, Rooholah [2 ]
Alimoghaddam, Kamran [2 ]
Ghavamzadeh, Ardeshir [2 ]
机构
[1] Shahid Beheshti Univ Med Sci, Fac Allied Med, Dept Hematol, Tehran, Iran
[2] Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, Iran
关键词
Pre-B ALL; Nalm-6; BIBR1532; survivin; p73; PANCREATIC-CANCER; SURVIVIN; APOPTOSIS; EXPRESSION; PATHWAY; RADIORESISTANCE; DISEASE; FAMILY; GENES; P73;
D O I
10.3109/10428194.2012.704034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since unlimited proliferative potential has been identified as a major and, to date, therapeutically unexploited phenotypic hallmark of cancer, telomere maintenance mechanisms have been proposed as potential targets for new anticancer interventions. This study was aimed to investigate the effects of BIBR1532, the lead compound of non-nucleosidic inhibition of telomerase, on pre-B acute lymphoblastic leukemia (ALL) cells. BIBR1532 caused rapid cell death in Nalm-6 cells probably through transcriptional suppression of survivin-mediated c-Myc and human telomerase reverse transcriptase (hTERT) expression in a concentration-dependent manner. Moreover, our results also suggest that induced p73, up-regulated Bax/Bcl-2 molecular ratio and subsequent activation of caspase-3 may contribute to a direct short-term cytotoxic effect of high doses of BIBR1532, independent of long-term substantial telomere erosion-mediated cell cycle arrest.
引用
收藏
页码:561 / 568
页数:8
相关论文
共 33 条
  • [1] Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate
    Pascolo, E
    Wenz, C
    Lingner, J
    Hauel, N
    Priepke, H
    Kauffmann, I
    Garin-Chesa, P
    Rettig, WJ
    Damm, K
    Schnapp, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (18) : 15566 - 15572
  • [2] Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells
    Bashash, Davood
    Zareii, Mohadeseh
    Safaroghli-Azar, Ava
    Omrani, Mir Davood
    Ghaffari, Seyed H.
    HEMATOLOGY, 2017, 22 (06) : 330 - 340
  • [3] Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells
    Feldhahn, N
    Klein, F
    Mooster, JL
    Hadweh, P
    Sprangers, M
    Wartenberg, M
    Bekhite, MM
    Hofmann, WK
    Herzog, S
    Jumaa, H
    Rowley, JD
    Müschen, M
    JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (11): : 1837 - 1852
  • [5] Drug Screening of Primary Human Pediatric Pre-B Cell Acute Lymphoblastic Leukemia (pre-B ALL) Cells in Their Stromal Niche
    Shieh, Jae-Hung
    Su, Tsann-Long
    Shieh, Jason
    Moore, Malcolm A. S.
    BLOOD, 2012, 120 (21)
  • [6] The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells
    Klein, F
    Feldhahn, N
    Harder, L
    Wang, H
    Wartenberg, M
    Hofmann, WK
    Wernet, P
    Siebert, R
    Müschen, M
    JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (05): : 673 - 685
  • [7] Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen
    Cardoso, AA
    Schultze, JL
    Boussiotis, VA
    Freeman, GJ
    Seamon, MJ
    Laszlo, S
    Billet, A
    Sallan, SE
    Gribben, JG
    Nadler, LM
    BLOOD, 1996, 88 (01) : 41 - 48
  • [8] The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells
    Ghasemimehr, Narges
    Farsinejad, Alireza
    Khalilabadi, Rooholla Mirzaee
    Yazdani, Zinat
    Fatemi, Ahmad
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 106 : 1742 - 1750
  • [9] CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia
    Pacenta, Holly L.
    Laetsch, Theodore W.
    John, Samuel
    PEDIATRIC DRUGS, 2020, 22 (01) : 1 - 11
  • [10] CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia
    Holly L. Pacenta
    Theodore W. Laetsch
    Samuel John
    Pediatric Drugs, 2020, 22 : 1 - 11